Modality
mRNA
MOA
IL-17i
Target
Nectin-4
Pathway
Angiogenesis
Heart Failure
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
Mar 2019
→ Jun 2028
Phase 3Current
NCT08064730
1,900 pts·Heart Failure
2022-01→2025-12·Not yet recruiting
NCT07522954
1,878 pts·Heart Failure
2019-03→2026-11·Completed
NCT03060691
978 pts·Heart Failure
2020-06→2028-06·Completed
4,756 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-12-213mo agoPh3 Readout· Heart Failure
2026-11-208mo awayPh3 Readout· Heart Failure
2028-06-222.2y awayPh3 Readout· Heart Failure
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2025-12-21 · 3mo ago
Heart Failure
Ph3 Readout
2026-11-20 · 8mo away
Heart Failure
Ph3 Readout
2028-06-22 · 2.2y away
Heart Failure
CompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08064730 | Phase 3 | Heart Failure | Not yet recr... | 1900 | CR |
| NCT07522954 | Phase 3 | Heart Failure | Completed | 1878 | UPCR |
| NCT03060691 | Phase 3 | Heart Failure | Completed | 978 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 |